Clinical Trials Logo

HPV-Related Malignancy clinical trials

View clinical trials related to HPV-Related Malignancy.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04679675 Completed - Cervical Cancer Clinical Trials

Self-Testing Options in the Era of Primary HPV Screening for Cervical Cancer Trial

STEP
Start date: November 20, 2020
Phase: N/A
Study type: Interventional

The Self-Testing options in the Era of Primary HPV screening for cervical cancer (STEP) trial will evaluate effectiveness of home-based HPV kits for improving cervical cancer screening uptake and its cost-effectiveness. The investigators will compare cervical cancer screening uptake within six months among women randomized to different outreach approaches based on prior screening behavior: A) Adherent and coming due: direct mail HPV kit vs. opt-in HPV kit vs. education; B) Overdue: direct mail HPV kit vs. education; C) Unknown: opt-in HPV kit vs. education.

NCT ID: NCT03749720 Completed - Clinical trials for HPV-Related Carcinoma

HPV in Blood Samples From Cervical Cancer Patients.

Start date: June 15, 2018
Phase: N/A
Study type: Interventional

By means of digital droplet PCR (ddPCR), this study examines blood samples from patients newly diagnosed with cervical cancer to investigate whether it is possible to measure the presence and amount of HPV DNA in these blood samples. The first blood sample is taken at time of diagnosis, and follow-up blood samples are collected during treatment- and follow-up visits. We expect to find a correlation between the disease stage and the viral load and also a decline in viral load after treatment. Furthermore, we hope that this method may serve as a way of detecting disease recurrence earlier than what is possible today.

NCT ID: NCT03451071 Completed - Clinical trials for HPV-Related Malignancy

Postpartum HPV Vaccination

Start date: April 29, 2019
Phase: Phase 4
Study type: Interventional

Human papillomavirus (HPV)-related cancers are on the rise in the United States. Furthermore, greater than 90% of cervical cancer cases are attributable to HPV, and cervical cancer disproportionately affects women of color in both incidence and mortality. Due to low HPV vaccine uptake in the US, innovative approaches to vaccinating vulnerable populations are necessary in order to maximize the cancer prevention potential of this vaccine. The puerperium is a time period when women are engaged in the healthcare system and have almost universal access to affordable health care. Two prior studies have shown that postpartum HPV vaccination is acceptable to patients, and high rates of vaccination were achieved in these primarily Hispanic populations. However, data show that the immune response in young women is less robust than in adolescents, and no studies have examined immunogenicity in postpartum women specifically. We propose an HPV vaccination pilot study in women who receive postpartum care at University of Alabama at Birmingham (UAB) hospital. We will examine the acceptability, uptake and immunogenicity of the vaccine in the postpartum setting.